Company:Maia Biotechnology

From HandWiki
MAIA Biotechnology, Inc.
TypePublic
NYSE: MAIA
IndustryBiotechnology, medicine
Key people
Vlad Vitoc (CEO, chairman), Sergei M. Gryaznov (Chief Scientific Officer)
Websitemaiabiotech.com

MAIA Biotechnology, Inc. is a public, immune-oncology[1] company based in Chicago, IL[2] focused on the development of telomere targeting agents for the treatment of telomerase-positive cancer cells.

History

In August 2022, the company's initial funding round closed, raising $10M.[3]

In March 2024, the company's equity fell below $500,000.[4] In April 2024, the company announced the completion of a $1 million private placement.[5]

Clinical trials

THIO-101

A phase II THIO-101 clinical trial of THIO sequenced with cemiplimab to treat advanced non-small cell lung cancer (NSCLC) continued in 2024. The trial is a multicentre, open-label, dose-finding trial designed to assess anti-tumour activity followed by PD-L1 inhibition. The study population was patients with advanced NSCLC who did not respond or developed resistance to first-line treatments using another checkpoint inhibitor. The trial's primary objectives are to assess tolerability, safety, and clinical efficacy using overall response rate (ORR) as the primary endpoint.[6]

In 2025, the FDA "Rare Pediatric Disease Designation" for THIO in treating pediatric-type diffuse high-grade gliomas (PDHGG), making MAIA eligible for a priority review voucher upon future FDA approval.[7]

Drug candidates

THIO (6-thio-2'-deoxyguanosine) is a drug that attempts to kill cells that express telomerase, which is found in 85% of human cancers.[1]

See also

References

  1. ↑ 1.0 1.1 Wang, Brian (2024-06-05). "Promising Possible Universal Cancer Treatment". https://nextbigfuture.substack.com/p/promising-possible-universal-cancer-treatmenthtml. 
  2. ↑ "EDGAR Entity Landing Page". https://www.sec.gov/edgar/browse/?CIK=0001878313. 
  3. ↑ Cornall, Jim (2022-08-02). "MAIA Biotechnology raises $10M from public offering" (in en-US). https://www.labiotech.eu/trends-news/maia-cancer-telomere/. 
  4. ↑ "MAIA Biotechnology at Risk of NYSE Delisting Over Equity Shortfalls - TipRanks.com" (in en-US). TipRanks Financial. https://www.tipranks.com/news/company-announcements/maia-biotechnology-at-risk-of-nyse-delisting-over-equity-shortfalls. 
  5. ↑ "MAIA Biotechnology Announces $1.00 Million Private Placement" (in en-US). https://www.biospace.com/article/maia-biotechnology-announces-1-00-million-private-placement/. 
  6. ↑ Priyan, Vishnu (2024-03-07). "MAIA Biotechnology reports positive data from NSCLC therapy trial" (in en-US). https://www.clinicaltrialsarena.com/news/maia-nsclc-therapy-trial-2/. 
  7. ↑ "FDA grants Rare Pediatric Disease designation for THIO in pediatric high-grade gliomas". The Cancer Letter. January 17, 2025. https://cancerletter.com/drugs-and-targets/20250117_9e/. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Company:Maia_Biotechnology&oldid=4069349"